Inovio launches mid-stage study of VGX-3100 in anal precancer

• Inovio Pharmaceuticals (NASDAQ:INO -3%) commences a Phase 2 clinical trial evaluating lead candidate VGX-3100 in adults men and women with human papillomavirus (HPV)-related anal dysplasia (the presence of abnormal cells that could develop into anal cancer).
• The open-label study will enroll ~24 subjects who will receive at least three doses of VGX-3100. According to ClinicalTrials.gov, the estimated completion date is August 2020.
• Anal cancer kills 1,100 Americans each year. The current standard of care for anal dysplasia is surgical excision, electrocautery or laser therapy. The post-treatment recurrence rate is greater than 50%.